Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Oral solid medicine composition for nervous system diseases

A technology of materials and adhesives, applied in nervous system diseases, drug combinations, cardiovascular system diseases, etc., can solve problems such as left ventricular enlargement and reduction, achieve elimination of half-life, improve brain energy metabolism, and inhibit brain mitochondria to generate peroxidation The effect of lipids

Active Publication Date: 2015-04-15
北京利龄恒泰药业有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Idebenone prevented iron-induced lipid peroxidation and myocardial injury in three patients given 5 mgkg daily for 4-9 months, resulting in a reduction in left ventricular enlargement in these patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral solid medicine composition for nervous system diseases
  • Oral solid medicine composition for nervous system diseases
  • Oral solid medicine composition for nervous system diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Example 1: Preparation of the pharmaceutical composition (tablet) of the present invention

[0083] Prescription for plain tablets:

[0084]

[0085] Preparation method:

[0086] i) Mix idebenone, anhydrous lactose and half of the disintegrant thoroughly;

[0087] ii) The binder povidone K30 is made into an aqueous solution (8%), and the powder material obtained in the previous step is made into soft material, granulated, and dried;

[0088] iii) Mix the dry granules with the rest of the disintegrant, lubricant and / or glidant, and compress them into the present invention

[0089] Tablets, which can be called tablet cores or plain tablets;

[0090] iv) Coating the tablets obtained in the above steps (using Opadry, prepared into a 14% aqueous suspension before use, with a coating weight gain of about 3%) to obtain a coated tablet of the pharmaceutical composition of the present invention.

Embodiment 2

[0091] Example 2: Preparation of the pharmaceutical composition (tablet) of the present invention

[0092] Prescription for plain tablets:

[0093]

[0094] Preparation method: basically the same as in Example 1. After determination, the weight ratio of idebenone to anhydrous lactose in the tablet is 30:80.23.

Embodiment 3

[0095] Example 3: Preparation of the pharmaceutical composition (tablet) of the present invention

[0096] Prescription for plain tablets:

[0097]

[0098] Preparation method: basically the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
hardnessaaaaaaaaaa
hardnessaaaaaaaaaa
Login to View More

Abstract

The invention relates to an oral solid medicine composition for nervous system diseases. The composition is a tablet and comprises an active component, lactose anhydrous, a disintegrating agent and an adhesive. The medicine composition can be used for a cerebrovascular disease, used for improving brain metabolism and mental symptoms, activating respiratory activity of brain mitochondria, improving brain energy metabolism of brain ischemia, increasing a utilization ratio of glucose in a brain, allowing adenosine triphosphate produced in the brain to be increased, preventing brain mitochondrion from generating peroxidized lipin, and inhibiting a membrane obstruction due to lipid peroxidation of a brain mitochondrial membrane, used for brain function injures caused by the chronic cerebrovascular disease, brain trauma and the like, and used for improving mental and behavioral disorders such as a subjective symptom, a language disorder, anxiety, depression, hypomnesia and brain power declining, promoting brain power, activating a brain mitochondrion function, improving the brain energy metabolism and a brain function, improving emotion depression, low consciousness, an affective disorder, a language disorder and the like that are caused by a cerebral infarction sequela, a cerebral hemorrhage sequela and cerebral arteriosclerosis, improving brain metabolism, and protecting cranial neural cells.

Description

Technical field [0001] The invention relates to an oral solid pharmaceutical composition for nervous system diseases. Background technique [0002] Neuronal damage, neurodegenerative diseases and syndromes (Alzheimer's disease, multiple sclerosis, Friedrich's ataxia), brain and spinal cord injuries and neurotraumatic injuries, stroke, Parkinson's disease, alcoholism And narcolepsy (narcolepsy), postoperative recovery syndrome and post-anaesthesia recovery syndrome) and many other diseases require effective treatment and prevention. [0003] Postoperative stroke and cognitive deficit (POSCD) syndrome is common, especially in elderly people undergoing extensive surgical procedures such as heart surgery or hip replacement surgery. In North America, more than 2.5 million such surgical procedures are performed each year, and the incidence of POSCD exceeds 30%. There is an urgent need for interventional therapy, and there are not enough treatment options for this painful postoperative ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/20A61K31/122A61K47/26A61P25/00A61P39/06A61P9/10A61P25/22A61P25/24A61P25/18A61P7/02A61P25/28A61P25/32
Inventor 刘炜
Owner 北京利龄恒泰药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com